Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Shareholder Meeting (November 2024)
24 slides from Island Pharmaceuticals's shareholder meeting presentation, Nov 19, 2024
Slide 1: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS DR DAVID FOSTER, MANAGING DIRECTOR Annual General Meeting, 19 November 2024 (ASX: ILA) ISLAND PHARMACEUTICALS 1 November 2024
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 3: Island Pharmaceuticals is an antiviral therapeutics company targeting infectious diseases
For personal use only Island Pharmaceuticals (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases ISLAND PHARMACEUTICALS 3 November 2024
Slide 4: Strategy: Rapid Paths to Market
For personal use only STRATEGY: - Known small molecules with clinical history - Mid/late stage clinical or other abbreviated routes - Open US FDA INDs - Validated US Govt/military funding support - Priority Review Voucher eligible RAPID PATHS TO MARKET ISLAND PHARMACEUTICALS 4 November 2024
Slide 5: A Year in Review
A YEAR IN REVIEW FY24 highlights FY25 to date For personal use only Single Ascending Next ISLA-101 Phase 2a Beneficiary of Filed Single Key US patent Dose study study renamed (preventative) USD 624k in DoD Ascending Dose granted for ISLA- successfully PROTECT and arm of ISLA-101 grant funding for st
Slide 6: About half of the world's population is now at risk of dengue
For personal use only “About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 30 May 2024 ISLAND PHARMACEUTICALS 6 November 2024
Slide 7: Dengue Is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE For personal use only ISLAND PHARMACEUTICALS 7 November 2024
Slide 8: Infection and Spread: Why the surge in dengue infections?
INFECTION AND SPREAD For personal use only Why the surge in dengue infections? Uninfected mosquito Warmer temperatures • Accelerate development • Increase activity of female mosquitoes • Reduce incubation time for mosquito to become Mosquito bites infectious 1-14 day How dengue infected person • All
Slide 9: Enter, the Tiger Mosquito (Aedes Albopictus)
ENTER, THE TIGER MOSQUITO (AEDES ALBOPICTUS) For personal use only • A new mosquito, Aedes Albopictus is on the scene • According to ECDC, the mosquito has been recorded as newly established in regions in France and Germany, and newly introduced into regions in Spain, the Netherlands, Portugal, and
Slide 10: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE For personal use only Prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.
Slide 11: About ISLA-101
For personal use only About ISLA-101 ISLAND PHARMACEUTICALS 11 November 2024
Slide 12: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection • In in-vitro models ISLA-101 has demonstrated broad anti-viral activity Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4
Slide 13: Prevents Animal Deaths from Lethal Dengue
PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE For personal use only ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISL
Slide 14: Phase 2a/b Dengue (PROTECT) Trial Study
PHASE 2a/b DENGUE (PROTECT) TRIAL STUDY For personal use only “PROTECT" study- A Phase 2a/b, Randomized, Double Phase 2a/b trial protocol: 2 cohorts blind, Placebo-controlled Dengue Challenge Study – a 1. Prophylactic Cohort- 2A: 4 subjects randomized 3:1 PROphylactic and TrEatment Challenge Trial 2
Slide 15: Phase 2a/b Clinical Trial Design
PHASE 2a/b CLINICAL TRIAL DESIGN For personal use only Phase 2a/b trial protocol: 2 cohorts Key near-term milestones: 1. Prophylactic Cohort- 2a (left): 4 subjects randomized 3:1 • Ethics approval received in August 2024, patient 2. Therapeutic Cohort: 2b (right): 10 subjects randomized 8:2 screenin
Slide 16: Why a Challenge Study?
WHY A CHALLENGE STUDY? For personal use only “When there are no available animal models of a disease, researchers take a weakened form of the virus and create a mild, safe form of the disease in a healthy person. The idea is that in a safe, well-controlled environment using a small number of people,
Slide 17: Phase 1 Control Data Demonstrates Benefit of Challenge Study Approach
PHASE 1 CONTROL DATA DEMONSTRATES BENEFIT OF CHALLENGE STUDY APPROACH For personal use only A Phase 1 challenge study conducted by Walter Reed and SUNY Upstate forms the basis of Island’s PROTECT study control data, and enabled unprecedented ability to monitor dengue symptoms, including: • Abdominal
Slide 18: Pipeline Build, Opportunities and Milestones
For personal use only PIPELINE BUILD, OPPORTUNITIES AND MILESTONES ISLAND PHARMACEUTICALS 18 November 2024
Slide 19: Strategic Checklist
STRATEGIC CHECKLIST For personal use only Clinical history Small molecule Proven preclinical anti-viral activity Eligible for Priority Review Vouchers National and military preparedness need Probable/confirmed non-dilutive funding to support: military, civilian, NGO Fit for our managem
Slide 20: Targeting Known or Re-purposable Drugs with Reduced Time to Market
TARGETING KNOWN OR RE-PURPOSABLE DRUGS WITH REDUCED TIME TO MARKET For personal use only GALIDESIVIR – Ebola, Marburg, Zika & and many other RNA viruses • 12 month, binding Letter of Intent signed 11 September 2024 • Substantial Phase I human safety data • Proven protective efficacy in a number of l
Slide 21: Commercial Opportunities
COMMERCIAL OPPORTUNITIES BOTH candidates have prophylactic and therapeutic potential For personal use only Travellers Military National Outbreaks Malaria is also a mosquito borne Relationship with US Army in Millions of patients in Latin disease and therefore a proxy for place (CRADA, ISLA101). Will
Slide 22: Corporate Snapshot
CORPORATE SNAPSHOT Key data Recent ILA trading history For personal use only Share price (AUD1) $0.175 Market cap1 $28m Shares on issue1 155,910,709 Listed Options2 30,584,956 Cash at 30 September 20243 $724k Placement announced 3 October 2024 $3.5m DoD grant funding to directly support Board of Dir
Slide 23: Key Milestones
KEY MILESTONES** For personal use only H1 FY 2025 H1 FY 2024 (Jul – Dec 2023) H2 FY 2024 (Jan – Jun 2024) H2 FY 2025 (Jan – Jun 2025) (Jul – Dec 2024) • Key US and Australian • Dose final Single • Obtain ethics approval • Subjects dosed in patents granted for Ascending Dose for Phase 2 trial Phase 2
Slide 24: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 24 November 2024
Island Pharmaceuticals — Shareholder Meeting (November 2024) on 6ix